Drug Eluting Balloon Market Overview

Drug Eluting Balloon (DEB) is a type of angioplasty balloon coated with anti-proliferative drugs that are delivered into the vessel wall during balloon inflation. These devices are widely used in the treatment of narrowed or blocked arteries and help reduce restenosis or blockage re-growth after treatment.

Drug eluting balloons are increasingly being adopted in interventional cardiology and peripheral vascular procedures due to their ability to provide targeted drug delivery while minimizing complications associated with conventional stenting procedures. Commonly used drugs in these balloons include paclitaxel, a cytotoxic and antineoplastic agent.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2321

The global drug eluting balloon market was valued at US$ 571.1 Mn in 2022 and is projected to reach US$ 1.0 Bn by the end of 2031, expanding at a CAGR of 7.1% from 2023 to 2031. Market growth is driven by increasing prevalence of cardiovascular disorders, high incidence of peripheral artery disease (PAD), and growing adoption of minimally invasive vascular procedures.

Analysis of Key Players in the Drug Eluting Balloon Market

The global drug eluting balloon market is highly competitive, with major players focusing on technological innovation, strategic acquisitions, and expansion of cardiovascular product portfolios.

Key companies operating in the market include:

• Bayer AG
  · Medtronic
  · B. Braun Melsungen AG
  · Cook Medical, Inc.
  · Boston Scientific Corporation
  · Becton, Dickinson and Company
  · EuroCor
  · Terumo Corporation
  · Koninklijke Philips N.V.
  · Other Prominent Players

These companies are investing in next-generation balloon technologies, image-guided procedures, and advanced drug delivery systems to strengthen their market position and improve treatment outcomes.

Key Developments in Global Drug Eluting Balloon Market

• On October 2, 2023, Cordis, a global leader in development and manufacture of interventional cardiovascular and endovascular technology, announced the acquisition of MedAlliance, a Switzerland-based developer of drug-eluting balloon technology. The acquisition is likely to improve the company’s coronary and peripheral vascular product portfolio.
• On August 9, 2023, Boston Scientific Corporation, a leading manufacturer of innovative medical solutions, announced it had received the U.S. Food and Drug Administration (FDA) approval for the POLARx Cryoablation System. This is a new system with unique capability of enabling two balloon sizes – 28 and 31mm – in one catheter.

Analysts’ Viewpoint on the Global Drug Eluting Balloon Market

Industry analysts highlight that the increasing burden of cardiovascular diseases and peripheral artery disease is a key driver of market expansion. Rising aging population, sedentary lifestyles, obesity, diabetes, and hypertension are significantly contributing to vascular disorders globally.

The growing preference for minimally invasive procedures over traditional open surgeries is transforming cardiovascular treatment approaches. Drug eluting balloons provide improved precision, lower complication risks, and faster patient recovery, making them highly attractive in interventional cardiology.

👉 Discuss Implications for Your Industry or Do you want customize Report, Please Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2321

Key Player Strategies

⚙️ Product Innovation
Development of advanced drug-coated balloon technologies and targeted drug delivery systems

🌐 Strategic Acquisitions
Expansion of cardiovascular portfolios through mergers and acquisitions

🏥 Focus on Minimally Invasive Procedures
Enhancing technologies for image-guided and robotic-assisted surgeries

🔬 R&D Investments
Research on next-generation angioplasty and vascular treatment devices

🌍 Geographical Expansion
Strengthening market presence in emerging healthcare markets

Challenges

• High cost associated with advanced cardiovascular procedures
• Stringent regulatory approval processes for medical devices
• Risk of restenosis and procedural complications in certain cases
• Limited healthcare access in underdeveloped regions

Opportunities

⚡ Rising Prevalence of Cardiovascular Diseases
Increasing patient pool requiring vascular intervention treatments

🏃 Growing Demand for Minimally Invasive Procedures
Preference for faster recovery and reduced hospitalization

🌱 Advancements in Interventional Cardiology
Development of innovative balloon and catheter technologies

🏥 Expansion of Healthcare Infrastructure
Improved treatment accessibility in emerging economies

🌍 Rising Awareness and Early Diagnosis
Growing focus on preventive cardiovascular care

Market Segmentation

By Product Type

• Coronary Drug Eluting Balloon
  • Peripheral Drug Eluting Balloon

By End-user

• Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

By Application

• Coronary Artery Disease
  • Peripheral Artery Disease
  • Others

By Region

• North America – Advanced healthcare infrastructure and reimbursement policies
  • Europe – Increasing adoption of cardiovascular technologies
  • Asia Pacific – Rising patient population and healthcare investments
  • Latin America
  • Middle East & Africa

Regional Outlook

North America is expected to dominate the global drug eluting balloon market during the forecast period due to developed healthcare infrastructure, high diagnosis rates, and easy availability of cardiovascular treatments. Government funding and reimbursement policies for chronic and cardiovascular diseases are further supporting market growth in the region.

The increasing prevalence of peripheral artery disease and heart-related conditions among the aging population is also driving demand for drug eluting balloons in North America.

Asia Pacific is projected to witness steady growth due to increasing healthcare expenditure, rising patient population, and growing demand for minimally invasive surgeries. Increasing prevalence of diabetes, obesity, and cardiovascular diseases in countries such as India and China is accelerating market expansion.

According to the World Health Organization 2023 report, approximately 77 million people aged above 18 years are suffering from diabetes in India, while nearly 25 million people are pre-diabetic, highlighting the growing cardiovascular risk burden in the region.

Why Invest in the Drug Eluting Balloon Market Analysis 2031

✅ Strong growth driven by rising cardiovascular and peripheral artery diseases

✅ Increasing preference for minimally invasive vascular procedures

✅ Technological advancements in interventional cardiology

✅ Expanding healthcare infrastructure in emerging economies

✅ High investment in R&D and innovative cardiovascular devices

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=2321&ltype=S

FAQs

1. What is the projected market size by 2031?
   The market is expected to reach US$ 1.0 Bn by 2031.
2. What is the CAGR of the market?
   The market is projected to grow at a CAGR of 7.1% from 2023 to 2031.
3. What factors are driving market growth?
   Rising prevalence of vascular diseases, growing demand for minimally invasive surgeries, and increasing incidence of peripheral artery disease.
4. Which region dominates the market?
   North America dominates due to advanced healthcare infrastructure and reimbursement support.
5. What are key trends in the market?
   Technological advancements in angioplasty balloons, growth in minimally invasive procedures, and expansion of targeted drug delivery systems.

More Trending Reports by Transparency Market Research –

Osteoporosis Drugs Market: https://www.transparencymarketresearch.com/osteoporosis-drug-market.html

Anti-Venom Market: https://www.transparencymarketresearch.com/anti-venom-market.html

Psychotropic Drugs Market: https://www.transparencymarketresearch.com/psychotropic-drugs-market.html

CAR T-cell Therapy Market: https://www.transparencymarketresearch.com/car-t-cell-therapy-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453